PRMA Consulting || Improving Pharmaceutical Market Access in Asia-Pacific
Agilent SLIMS
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

AstraZeneca and Oncoshot establish strategic partnership to better streamline recruitment process for cancer clinical trials

Friday, September 24, 2021

Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that the United States Patent and Trademark Office has issued a new patent titled, "Enriched Multilayer Amnion Derived Tissue Graft." The new patent strengthens Amnio Technology's intellectual property position by further protecting its advanced allograft manufacturing processes in the United States.

"This newest patent issuance highlights the investments Amnio Technology has made in the areas of human tissue-based product manufacturing excellence and clinical utility" said Senior Director of New Product Development, Rob Diller, PhD. "The fact that we are able to protect the intellectual property of our continued allograft research speaks to the high caliber of our research team."

Amnio Technology holds a total of five U.S.-issued patents. The Company's intellectual property is also protected in the European Union by the patent, "Acellular Amnion Derived Therapeutic Compositions," issued this year.

William Brown, Managing Director of Operations, echoed Dr. Diller's sentiment, "Through the dedicated and purposeful work of our Scientific and Research Teams, Amnio Technology continues to develop and provide products that improve patient quality of life. We are pleased that our advancements in regenerative medicine are continuously recognized by the United States Patent and Trademark Office and its international counterparts."

Latest Issue
Get instant
access to our latest e-book
Saving Money, Saving Time In Pharma Operations Thermo Fisher Scientific || Revolutionize your mAb manufacturing Kerry || Webinar || Coatings Change Control Webinar || Recording-Webinar Rousselot || X-PureĀ® GelMA Meco - 90 years Medical Fair Thailand 2022